ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1176

Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts

Aurélien Chepy1, Marie Duhamel2, Solange Vivier3, lucile Guilbert3, Eric Hachulla4, Sylvain Dubucquoi3, David Launay3, Michel Salzet2 and Vincent Sobanski3, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, 3Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, 4University of Lille, LILLE, France

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), autoimmune diseases, Fibroblasts, Dermal, proteomics, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc).Recently, it has been shown that immunoglobulins G (IgG) from SSc promoted a proinflammatory and profibrotic phenotype in monocytes secretome. Fibroblasts (FB) are key effectors cells in SSc and data on FB proteins secretion in the presence of IgG from SSc patients are lacking. Our objective was to explore the FB secretome in the presence of purified IgG from SSc patients.

Methods: Normal dermal FB were cultured in the presence of purified IgG from patients with diffuse cutaneous SSc (dcSSc) (n=20 [of whom 10 were anti-topoisomerase-I (ATA) positive and 10 were ATA negative]), limited cutaneous SSc anti-centromere positive (lcSSc ACA+) (n=10) or healthy controls (HC (n=10). After 72h of culture, the cell supernatants were collected, centrifuged and passed through a filter to remove the cells. After proteins digestion, secretome was explored using mass spectrometry coupled with liquid chromatography (LC-MS/MS). Analysis of variance (ANOVA) and hierarchical clustering were used to identify proteins responses patterns.

Results: Proteomics identified and quantified 1,268 proteins, among them 377 were significant after ANOVA. SSc and HC secretomes appeared distinct. Hierarchical clustering on significant proteins after ANOVA identified 3 clusters: C1 including mostly dcSSc ATA+ patients, C2 including mostly dcSSc ATA- patients, C3 was more heterogeneous including the majority of HC, lcSSc ACA+ patients and some dcSSc ATA- patients (figure 1). We then studied proteins patterns in the initial groups of subjects. Three main clusters were highlighted. C(a) regrouped 95 proteins which were overexpressed in the presence of purified IgG from dcSSc ATA+ patients (involved in calcium-dependent binding and extracellular matrix constituents). C(b) included 248 proteins mostly underexpressed in the presence of purified IgG from dcSSc ATA+ patients (involved in protein folding and actin filament depolymerization). C(c) gathered 34 proteins overexpressed in presence of purified IgG from all SSc groups (involved in amyloid-beta binding and ECM structural constituents) (figure 2). Finally, we performed differential analyses. Follistatin, amyloid beta A4 protein, myosin-9 and calreticulin were commonly overexpressed in all SSc subtypes. We identified 19 proteins exclusively overexpressed in dcSSc ATA positive patients such as collagen alpha-I type 7 and galectin 3 binding proteins (figure 3).

Conclusion: Using sensitive proteomic approach, we highligthed that purified IgG from SSc patients can modify the FB secretome. Along with similar results on monocyte secretome, these data suggest that SSc-IgG may influence the inflammatory and fibrotic phenotype of different cells.

Supporting image 1

Heatmap representing the 377 differentially expressed proteins after ANOVA in all samples. Cluster analysis identified 3 clusters (C1, C2 and C3).
IgG HC: purified IgG from healthy controls; IgG dcSSc ATA+: purified IgG from diffuse systemic sclerosis anti-topoisomerase-I positive patients; IgG dcSSc ATA-: purified IgG from diffuse systemic sclerosis anti-topoisomerase-I negative patients; IgG lcSSc ACA+: purified IgG from limited systemic sclerosis anti-centromere positive patients. ANOVA: analysis of variance.

Supporting image 2

Heatmap representing proteins clusters (C(a), C(b) and C(c)) according to the initial groups of subjects.
IgG HC: purified IgG from healthy controls; IgG dcSSc ATA+: purified IgG from diffuse systemic sclerosis anti-topoisomerase-I positive patients; IgG dcSSc ATA-: purified IgG from diffuse systemic sclerosis anti-topoisomerase-I negative patients; IgG lcSSc ACA+: purified IgG from limited systemic sclerosis anti-centromere positive patients.

Supporting image 3

Commonly overexpressed proteins in SSc (all serotypes) (A); Proteins exclusively overexpressed in dcSSc ATA+ (B).
DEP: differentially expressed proteins; SSc: systemic sclerosis; IgG HC: purified IgG from healthy controls; IgG dcSSc ATA+: purified IgG from diffuse systemic sclerosis anti-topoisomerase-I positive patients; IgG dcSSc ATA-: purified IgG from diffuse systemic sclerosis anti-topoisomerase-I negative patients; IgG lcSSc ACA+: purified IgG from limited systemic sclerosis anti-centromere positive patients.


Disclosures: A. Chepy, None; M. Duhamel, None; S. Vivier, None; l. Guilbert, None; E. Hachulla, GlaxoSmithKline, Johnson & Johnson, Roche-Chugai, CSL Behring, Bayer, Boehringer Ingelheim, Sanofi-Genzyme; S. Dubucquoi, None; D. Launay, None; M. Salzet, None; V. Sobanski, None.

To cite this abstract in AMA style:

Chepy A, Duhamel M, Vivier S, Guilbert l, Hachulla E, Dubucquoi S, Launay D, Salzet M, Sobanski V. Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/immunoglobulins-g-from-systemic-sclerosis-patients-may-alter-the-secretome-of-dermal-fibroblasts/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunoglobulins-g-from-systemic-sclerosis-patients-may-alter-the-secretome-of-dermal-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology